Center for Scientific Review; Notice of Closed Meetings, 39321 [E8-15469]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 132 / Wednesday, July 9, 2008 / Notices
jlentini on PROD1PC65 with NOTICES
Inventors: Snorri Thorgeirsson (NCI)
and Cedric Coulouaran (NCI)
Relevant Publication: Coulouaran C,
Factor VM, Thorgeirsson SS.
Transforming growth factor-beta gene
expression signature in mouse
hepatocytes predicts clinical outcome in
human cancer. Hepatology 2008
Jun;47(6):2059–2067.
Patent Status: U.S. Provisional
Application No. 60/981,661 filed 22 Oct
2007 (HHS Reference No. E–282–2007/
0-US–01)
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Center for
Cancer Research, Laboratory of
Experimental Carcinogenesis is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize a novel temporal TGFbeta gene expression signature that
predicts HCC patient clinical outcomes.
Please contact John D. Hewes, PhD at
301–435–3121 or hewesj@mail.nih.gov
for more information.
A New Pot1 Variant Gene as a
Diagnostic Biomarker for Hereditary
Non-polyposis Colorectal Cancer
Description of Technology: The
diagnosis of Hereditary Nonpolyposis
Colorectal Cancer (HNPCC) is difficult
because the disease lacks phenotypic
signs that might facilitate its
presymptomatic diagnosis. This
invention is based on the identification
of a new splice variant of a gene that
appears to exist specifically in HNPCC,
namely ‘‘Pot1’’ or ‘‘Protection of
Telomeres.’’ Pot1 has a critical role in
ensuring chromosome stability by
binding to telomeres. The invention
presents a variant of Pot1 that is present
in mismatch repair-deficient, but not
proficient, cancer cell lines and
primary, non-tumor tissue samples. The
presence of this variant may be useful
both as a diagnostic marker for HNPCC,
and as a new therapeutic target for the
treatment of HNPCC.
Applications and Modality:
Identification of new ‘‘Pot1’’ variant
gene associated with HNPCC
New gene can be used as a potential
diagnostic biomarker for the diagnosis
of HNPCC.
Pot1 as a new therapeutic target for
the treatment of HNPCC.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Qin Yang and Curtis C.
Harris (NCI).
Related Publications:
VerDate Aug<31>2005
16:15 Jul 08, 2008
Jkt 214001
1. P Baumann et al. Human Pot1
(protection of telomeres) protein:
cytolocalization, gene structure, and
alternative splicing. Mol Cell Biol. 2002
Nov;22(22):8079–8087.
2. A Umar et al. Revised Bethesda
Guidelines for hereditary nonpolyposis
colorectal cancer (Lynch syndrome) and
microsatellite instability. J Natl Cancer
Inst. 2004 Feb 18;96(4):261–268.
3. HT Lynch et al. Hereditary
nonpolyposis colorectal carcinoma
(HNPCC) and HNPCC-like families:
Problems in diagnosis, surveillance, and
management. Cancer. 2004 Jan
1;100(1):53–64.
4. Q Yang et al. Functional diversity
of human protection of telomeres 1
isoforms in telomere protection and
cellular senescence. Cancer Res. 2007
Dec 15;67(24):11677–11686.
Patent Status: U.S. Provisional
Application No. 60/620,754 filed 20 Oct
2004 (HHS Reference No. E–263–2004/
0–US–01), entitled ‘‘POT1 Alternating
Splice Variants’’
International Patent Application No.
PCT/US2005/037957 filed 19 Oct 2005,
which published as WO 2006/045062
on 27 Apr 2006 (HHS Reference No. E–
263–2004/0–PCT–02)
U.S. Patent Application No. 11/
665,944 filed 20 Apr 2007 (HHS
Reference No. E–263–2004/0-US–03).
Licensing Status: Available for
exclusive and non-exclusive licensing.
Licensing Contact: Surekha Vathyam,
PhD; 301–435–4076;
vathyams@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute
Laboratory of Human Carcinogenesis is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
biomarkers of colon cancer. Please
contact John D. Hewes, PhD at 301–435–
3121 or hewesj@mail.nih.gov for more
information.
Dated: June 30, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–15562 Filed 7–8–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
39321
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(cX6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Gene
Therapy and Inborn Errors-2.
Date: July 14, 2008.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call)
Contact Person: Richard Panniers, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2212,
MSC 7890, Bethesda, MD 20892, (301) 435–
1741, pannierr@csr.nih.gov.
This notice is being published less
than 15 days prior to the meeting due
to the timing limitations imposed by the
review and funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Review of
Member Conflict Applications from BSPH
and ACE.
Date: July 28, 2008.
Time: 10 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call)
Contact Person: Mark P. Rubert, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–435–
1775, rubertm@csr.nih.gov.
This notice is being published less
than 15 days prior to the meeting due
to the timing limitations imposed by the
review and funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: July 1, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–15469 Filed 7–8–08; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\09JYN1.SGM
09JYN1
]]>Agencies
[Federal Register Volume 73, Number 132 (Wednesday, July 9, 2008)]
[Notices]
[Page 39321]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-15469]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(cX6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Gene Therapy and Inborn Errors-2.
Date: July 14, 2008.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892. (Telephone Conference Call)
Contact Person: Richard Panniers, PhD, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2212, MSC 7890, Bethesda, MD
20892, (301) 435-1741, pannierr@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and funding
cycle.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Review of Member Conflict Applications from BSPH and ACE.
Date: July 28, 2008.
Time: 10 a.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892. (Telephone Conference Call)
Contact Person: Mark P. Rubert, PhD, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301-435-
1775, rubertm@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and funding
cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: July 1, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-15469 Filed 7-8-08; 8:45 am]
BILLING CODE 4140-01-M
